New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

Genitourinary cancers require individualized treatment plans based on type, stage, and patient health, utilizing imaging, biopsy, and various therapies. Combining therapies with complementary ...

Universal testing for pathogenic germline variants in patients with genitourinary cancers identifies potentially actionable variants that may be missed with guideline-based testing, new research ...

Siamak Daneshmand, MD, provides closing remarks on the management of genitourinary cancers and the future of care. This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.

Recent years have seen remarkable progress in the application of radiotherapy for the management of genitourinary (GU) malignancies, including prostate, ...

Cancer care is undergoing a quiet but profound transformation, driven by technology, better understanding of disease biology, and a growing emphasis on quality of life.

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

HPN328 yielded responses in patients with genitourinary neuroendocrine carcinoma and other neuroendocrine cancers in a phase 1/2 trial. HPN328 has demonstrated “promising clinical activity” in ...

Universal genetic testing at an institution identified pathogenic germline variants in 14% of patients with genitourinary cancer. More than 1 in 8 patients with genitourinary malignancies in a recent ...

Incorporating Molecular Data Into Treatment Decision Making in Gastroesophageal and Pancreaticobiliary Cancers: Timing and Strategies Palliative care (PC) plays a critical role in managing the ...

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) ...

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including three accepted ...